<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">FibroGENE: A gene-based model for staging liver fibrosis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Mohammed</forename><surname>Eslam</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Storr Liver Centre</orgName>
								<orgName type="institution" key="instit1">The Westmead Millennium Institute for Medical Research and Westmead Hospital</orgName>
								<orgName type="institution" key="instit2">the University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ahmed</forename><forename type="middle">M</forename><surname>Hashem</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Systems and Biomedical Engineering</orgName>
								<orgName type="department" key="dep2">Faculty of Engineering</orgName>
								<orgName type="institution">Minia University</orgName>
								<address>
									<region>Minia</region>
									<country key="EG">Egypt</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Manuel</forename><surname>Romero-Gomez</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Unit for The Clinical Management of Digestive Diseases and CIBERehd</orgName>
								<orgName type="institution">Hospital Universitario de Valme</orgName>
								<address>
									<settlement>Sevilla</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Berg</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Medizinische Klinik m.S. Hepatologie und Gastroenterologie</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Charite</settlement>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Universit√§tsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Hepatology</orgName>
								<orgName type="department" key="dep2">Clinic for Gastroenterology and Rheumatology</orgName>
								<orgName type="institution">University Clinic Leipzig</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gregory</forename><forename type="middle">J</forename><surname>Dore</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">Kirby Institute</orgName>
								<orgName type="institution" key="instit2">The University of New South Wales</orgName>
								<address>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution">St Vincent&apos;s Hospital</orgName>
								<address>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alessandra</forename><surname>Mangia</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Division of Hepatology</orgName>
								<orgName type="institution">IRCCS</orgName>
								<address>
									<addrLine>Ospedale Casa Sollievo della Sofferenza</addrLine>
									<settlement>San Giovanni Rotondo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Henry</forename><surname>Lik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yuen</forename><surname>Chan</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Medicine and Therapeutics</orgName>
								<orgName type="institution" key="instit1">Prince of Wales Hospital</orgName>
								<orgName type="institution" key="instit2">The Chinese University of Hong Kong</orgName>
								<address>
									<settlement>Hong Kong</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">William</forename><forename type="middle">L</forename><surname>Irving</surname></persName>
							<affiliation key="aff11">
								<orgName type="laboratory">NIHR Biomedical Research Unit in Gastroenterology and the Liver</orgName>
								<orgName type="institution">University of Nottingham</orgName>
								<address>
									<settlement>Nottingham</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Sheridan</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Institute of Cellular Medicine</orgName>
								<orgName type="department" key="dep2">Medical School</orgName>
								<orgName type="laboratory">Liver Research Group</orgName>
								<orgName type="institution">Newcastle University</orgName>
								<address>
									<settlement>Newcastle upon Tyne</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Institute of Translational and Stratified Medicine</orgName>
								<orgName type="institution">Plymouth University</orgName>
								<address>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><forename type="middle">Lorena</forename><surname>Abate</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="department" key="dep2">Department of Medical Science</orgName>
								<orgName type="institution">University of Turin</orgName>
								<address>
									<settlement>Turin</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Leon</forename><forename type="middle">A</forename><surname>Adams</surname></persName>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">School of Medicine and Pharmacology</orgName>
								<orgName type="department" key="dep2">Sir Charles Gairdner Hospital Unit</orgName>
								<orgName type="institution">University of Western Australia</orgName>
								<address>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Weltman</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Nepean Hospital</orgName>
								<address>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elisabetta</forename><surname>Bugianesi</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="department" key="dep2">Department of Medical Science</orgName>
								<orgName type="institution">University of Turin</orgName>
								<address>
									<settlement>Turin</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrich</forename><surname>Spengler</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">University of Bonn</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olfat</forename><surname>Shaker</surname></persName>
							<affiliation key="aff18">
								<orgName type="department" key="dep1">Medical Biochemistry and Molecular Biology Department</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">Cairo University</orgName>
								<address>
									<settlement>Cairo</settlement>
									<country key="EG">Egypt</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Janett</forename><surname>Fischer</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Medizinische Klinik m.S. Hepatologie und Gastroenterologie</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Charite</settlement>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Universit√§tsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lindsay</forename><surname>Mollison</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">School of Medicine and Phramacology</orgName>
								<orgName type="institution" key="instit1">Fremantle Hospital</orgName>
								<orgName type="institution" key="instit2">UWA</orgName>
								<address>
									<settlement>Fremantle</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wendy</forename><surname>Cheng</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Department of Gastroenterology &amp; Hepatology</orgName>
								<orgName type="institution">Royal Perth Hospital</orgName>
								<address>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jacob</forename><surname>Nattermann</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">University of Bonn</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephen</forename><surname>Riordan</surname></persName>
							<affiliation key="aff21">
								<orgName type="laboratory">Gastrointestinal and Liver Unit</orgName>
								<orgName type="institution" key="instit1">Prince of Wales Hospital</orgName>
								<orgName type="institution" key="instit2">University of New South Wales</orgName>
								<address>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Kebitsaone</roleName><forename type="first">Luca</forename><surname>Miele</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Catholic University of the Sacred Heart</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Simon</forename><surname>Kelaeng</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Javier</forename><surname>Ampuero</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Unit for The Clinical Management of Digestive Diseases and CIBERehd</orgName>
								<orgName type="institution">Hospital Universitario de Valme</orgName>
								<address>
									<settlement>Sevilla</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Golo</forename><surname>Ahlenstiel</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Storr Liver Centre</orgName>
								<orgName type="institution" key="instit1">The Westmead Millennium Institute for Medical Research and Westmead Hospital</orgName>
								<orgName type="institution" key="instit2">the University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Duncan</forename><surname>Mcleod</surname></persName>
							<affiliation key="aff23">
								<orgName type="department" key="dep1">Department of Anatomical Pathology</orgName>
								<orgName type="department" key="dep2">Institute of Clinical Pathology and Medical Research (ICPMR)</orgName>
								<orgName type="institution">Westmead Hospital</orgName>
								<address>
									<settlement>Sydney</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elizabeth</forename><surname>Powell</surname></persName>
							<affiliation key="aff24">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Princess Alexandra Hospital</orgName>
								<address>
									<settlement>Woolloongabba</settlement>
									<region>QLD</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff25">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution" key="instit1">The University of Queensland</orgName>
								<orgName type="institution" key="instit2">Princess Alexandra Hospital</orgName>
								<address>
									<settlement>Woolloongabba</settlement>
									<region>QLD</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christopher</forename><surname>Liddle</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Storr Liver Centre</orgName>
								<orgName type="institution" key="instit1">The Westmead Millennium Institute for Medical Research and Westmead Hospital</orgName>
								<orgName type="institution" key="instit2">the University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><forename type="middle">W</forename><surname>Douglas</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Storr Liver Centre</orgName>
								<orgName type="institution" key="instit1">The Westmead Millennium Institute for Medical Research and Westmead Hospital</orgName>
								<orgName type="institution" key="instit2">the University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">R</forename><surname>Booth</surname></persName>
							<affiliation key="aff26">
								<orgName type="department">Institute of Immunology and Allergy Research</orgName>
								<orgName type="institution" key="instit1">Westmead Hospital and Westmead Millennium Institute</orgName>
								<orgName type="institution" key="instit2">University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kebitsaone</forename><forename type="middle">Simon</forename><surname>Kelaeng</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Storr Liver Centre</orgName>
								<orgName type="institution" key="instit1">The Westmead Millennium Institute for Medical Research and Westmead Hospital</orgName>
								<orgName type="institution" key="instit2">the University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Jacob</forename><surname>George</surname></persName>
							<email>jacob.george@sydney.edu.au</email>
							<affiliation key="aff1">
								<orgName type="department">Storr Liver Centre</orgName>
								<orgName type="institution" key="instit1">The Westmead Millennium Institute for Medical Research and Westmead Hospital</orgName>
								<orgName type="institution" key="instit2">the University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Reynold</forename><surname>Leung</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Storr Liver Centre</orgName>
								<orgName type="institution" key="instit1">The Westmead Millennium Institute for Medical Research and Westmead Hospital</orgName>
								<orgName type="institution" key="instit2">the University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff26">
								<orgName type="department">Institute of Immunology and Allergy Research</orgName>
								<orgName type="institution" key="instit1">Westmead Hospital and Westmead Millennium Institute</orgName>
								<orgName type="institution" key="instit2">University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rose</forename><surname>White</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Storr Liver Centre</orgName>
								<orgName type="institution" key="instit1">The Westmead Millennium Institute for Medical Research and Westmead Hospital</orgName>
								<orgName type="institution" key="instit2">the University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Antony</forename><surname>Rahme</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Storr Liver Centre</orgName>
								<orgName type="institution" key="instit1">The Westmead Millennium Institute for Medical Research and Westmead Hospital</orgName>
								<orgName type="institution" key="instit2">the University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Angela</forename><surname>Rojas</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Unit for The Clinical Management of Digestive Diseases and CIBERehd</orgName>
								<orgName type="institution">Hospital Universitario de Valme</orgName>
								<address>
									<settlement>Sevilla</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rocio</forename><surname>Gallego-Duran</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Unit for The Clinical Management of Digestive Diseases and CIBERehd</orgName>
								<orgName type="institution">Hospital Universitario de Valme</orgName>
								<address>
									<settlement>Sevilla</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Margaret</forename><surname>Bassendine</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Institute of Cellular Medicine</orgName>
								<orgName type="department" key="dep2">Medical School</orgName>
								<orgName type="laboratory">Liver Research Group</orgName>
								<orgName type="institution">Newcastle University</orgName>
								<address>
									<settlement>Newcastle upon Tyne</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vincent</forename><forename type="middle">W S</forename><surname>Wong</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Medicine and Therapeutics</orgName>
								<orgName type="institution" key="instit1">Prince of Wales Hospital</orgName>
								<orgName type="institution" key="instit2">The Chinese University of Hong Kong</orgName>
								<address>
									<settlement>Hong Kong</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chiara</forename><surname>Rosso</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="department" key="dep2">Department of Medical Science</orgName>
								<orgName type="institution">University of Turin</orgName>
								<address>
									<settlement>Turin</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lavinia</forename><surname>Mezzabotta</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="department" key="dep2">Department of Medical Science</orgName>
								<orgName type="institution">University of Turin</orgName>
								<address>
									<settlement>Turin</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vijayaprakash</forename><surname>Suppiah</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Storr Liver Centre</orgName>
								<orgName type="institution" key="instit1">The Westmead Millennium Institute for Medical Research and Westmead Hospital</orgName>
								<orgName type="institution" key="instit2">the University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Monika</forename><surname>Michalk</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Nepean Hospital</orgName>
								<address>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Barbara</forename><surname>Malik</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Hepatology</orgName>
								<orgName type="department" key="dep2">Clinic for Gastroenterology and Rheumatology</orgName>
								<orgName type="institution">University Clinic Leipzig</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gail</forename><surname>Matthews</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">St Vincent&apos;s Hospital</orgName>
								<address>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tanya</forename><surname>Applegate</surname></persName>
							<affiliation key="aff26">
								<orgName type="department">Institute of Immunology and Allergy Research</orgName>
								<orgName type="institution" key="instit1">Westmead Hospital and Westmead Millennium Institute</orgName>
								<orgName type="institution" key="instit2">University of Sydney</orgName>
								<orgName type="institution" key="instit3">NSW</orgName>
								<address>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jason</forename><surname>Grebely</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">Kirby Institute</orgName>
								<orgName type="institution" key="instit2">The University of New South Wales</orgName>
								<address>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vincenzo</forename><surname>Fragomeli</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Nepean Hospital</orgName>
								<address>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Julie</forename><forename type="middle">R</forename><surname>Jonsson</surname></persName>
							<affiliation key="aff24">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Princess Alexandra Hospital</orgName>
								<address>
									<settlement>Woolloongabba</settlement>
									<region>QLD</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rosanna</forename><surname>Santaro</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Hepatology</orgName>
								<orgName type="department" key="dep2">Clinic for Gastroenterology and Rheumatology</orgName>
								<orgName type="institution">University Clinic Leipzig</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Division of Hepatology</orgName>
								<orgName type="institution">IRCCS</orgName>
								<address>
									<addrLine>Ospedale Casa Sollievo della Sofferenza</addrLine>
									<settlement>San Giovanni Rotondo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">International Liver Disease Genetics Consortium (ILDGC)</orgName>
								<address>
									<settlement>George</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff27">
								<orgName type="department">Department of Medicine Westmead Hospital Westmead</orgName>
								<address>
									<postCode>2145</postCode>
									<region>NSW</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">FibroGENE: A gene-based model for staging liver fibrosis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">53AB5F5F9FEEE187492013DEC1A8920E</idno>
					<idno type="DOI">10.1016/j.jhep.2015.11.008</idno>
					<note type="submission">Received Date: 8 July 2015 Revised Date: 2 November 2015 Accepted Date: 9 November 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Chronic hepatitis C</term>
					<term>Chronic hepatitis B</term>
					<term>non alcoholic steatohepatitis</term>
					<term>NASH</term>
					<term>IFNL</term>
					<term>fibrosis</term>
					<term>data mining analysis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Number of figures and tables: 2 tables, 2 figures.</head><p><s>Acknowledgements: We would like to thank all the patients for their participation in this study.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Irrespective of the underlying disease, hepatic fibrosis culminating in cirrhosis is the principal cause of chronic liver disease related morbidity and mortality <ref type="bibr" target="#b0">[1]</ref>.</s><s>Among such diseases, chronic hepatitis B (CHB), chronic hepatitis C (CHC) and fatty liver disease (NAFLD) are the most common worldwide <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s></p><p><s>Studies over several decades have established that the severity of hepatic fibrosis affects long term outcomes, and hence, clinical management and treatment, as reviewed elsewhere <ref type="bibr" target="#b3">[4]</ref>.</s></p><p><s>For example, the complications of advanced fibrosis such as portal hypertension, ascites and hepatocellular carcinoma are all associated with reduced survival <ref type="bibr" target="#b3">[4]</ref>.</s><s>Thus, clinical decision making is to a large extent based on accurate staging of liver fibrosis.</s><s>Once this has been established, clinicians typically also consider baseline predictors of fibrosis progression to come to a personalized management algorithm.</s></p><p><s>Although invasive, limited by sampling error and inter-observer variability, liver biopsy is still considered the 'Gold Standard' for the assessment of liver disease stage <ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref>.</s><s>At present, several non-invasive methods for the assessment of liver fibrosis based on panels of serum markers, or the measurement of liver stiffness by elastography, are widely used as surrogate measures.</s><s>However, these methods are also not free of limitations.</s><s>For example, biomarker panels fluctuate during concurrent illnesses, reproducibility is a concern, and many components of such panels do not directly reflect the underlying disease process <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>.</s><s>Likewise, transient elastography is limited by reduced performance in obese patients, and interference by concomitant inflammation and steatosis <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11]</ref>.</s><s>These concerns about reproducibility and over-or under-estimation of fibrosis stage are even more problematic for non-CHC diseases such as CHB <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref> and NAFLD <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref>.</s></p><p><s>In this context, incorporation of an invariant genetic marker of liver fibrosis risk to algorithms for fibrosis prediction could be useful, but has not previously been described.</s><s>We recently reported that single-nucleotide polymorphisms (rs12979860) in the intronic region of the interferon-Œª4 (IFNL4) gene modulate liver inflammation and fibrosis, in an etiology independent manner <ref type="bibr" target="#b15">[16]</ref>.</s><s>Thus, it could be hypothesized that this polymorphism, a test for which is widely used and commonly available, might have a role in algorithms that predict fibrosis.</s><s>We sought to apply an unbiased data mining approach to build a novel IFNL-dependent fibrosis prediction algorithm, in combination with routinely available clinical and laboratory data.</s><s>We envisaged that the algorithm could be utilized in clinical practice to assess the risk for significant fibrosis and to aid in decision making.</s><s>We compared our model to two existing noninvasive indices, FIB-4 and APRI, and in the cohort with NAFLD, also to the NAFLD fibrosis score (NFS) and the Forns' index, that does not require additional laboratory testing.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient cohort</head><p><s>The cohort comprised 4277 patients with chronic hepatitis C, chronic hepatitis B and NAFLD accrued from contributing centers to the International Liver Disease Genetics Consortium (ILDGC).</s><s>The ILDGC included patients from 20 tertiary and academic centers from 7 countries (Australia, the United Kingdom, Italy, Germany, Spain, Egypt and Hong Kong).</s><s>The details of the cohort and inclusion criteria have been reported previously <ref type="bibr" target="#b15">[16]</ref>.</s><s>Briefly, for patients with chronic hepatitis C, all consecutive patients who had a liver biopsy before antiviral therapy, with scoring for fibrosis stage and disease activity between 1999 and 2011, were included.</s><s>Patients were excluded if they had evidence of other liver diseases by standard tests.</s></p><p><s>For the current analysis, predictors of significant fibrosis were determined from an initial derivation cohort with hepatitis C (n=1992).</s><s>These data were subject to several machine learning techniques to develop the best model for the prediction of significant fibrosis (F2/3/4 by METAVIR) <ref type="bibr" target="#b16">[17]</ref>.</s><s>For independent validation, a further 1242 patients with chronic hepatitis C were enrolled from 2 additional centers.</s></p><p><s>Based on our recent hypothesis that IFNL genotype is a core variant associated with liver fibrosis independent of disease etiology <ref type="bibr" target="#b15">[16]</ref>, we tested the validity of the model in 555 patients with chronic hepatitis B (CHB) and 488 with nonalcoholic fatty liver disease (NAFLD).</s></p><p><s>Ethics approval was obtained from the Human Research Ethics Committees of the Sydney West Local Health District and the University of Sydney.</s><s>All other sites had ethics approval from their respective ethics committees.</s><s>Written informed consent for genetic testing was obtained from all participants.</s><s>The study was conducted in accordance with ethical guidelines of the International Conference on Harmonization Guidelines for Good Clinical Practice <ref type="bibr" target="#b18">[18]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical and laboratory assessment</head><p><s>The following data were collected at time of liver biopsy for all patients: gender, age, ethnicity, recruitment center, alcohol intake, body mass index (BMI), and routine laboratory tests.</s><s>Alcohol consumption was assessed by 2 separate interviews with the patient and close family members.</s><s>BMI was calculated as weight divided by the square of the height (kg/m 2 ).</s><s>Data on cardio-metabolic status was collected for the NASH cohort and considered as variables in the construction of models for prediction of fibrosis.</s><s>The diagnosis of arterial hypertension was according to standard international criteria <ref type="bibr" target="#b19">[19]</ref>.</s></p><p><s>The FibroGENE-DT model we developed was compared to three popular noninvasive indexes that do not require additional laboratory testing.</s><s>The AST to platelet ratio index (APRI) was calculated according to the formula: (AST (IU/L)/upper normal limit) √ó 100/platelets (10 9 /L) <ref type="bibr" target="#b21">[20]</ref>.The FIB-4 index was calculated as follows: age (years) √ó AST (IU/L)/(platelets (10 9 /L) √ó (ALT(IU/L)) ¬Ω ) <ref type="bibr" target="#b23">[21]</ref>.</s><s>In the NAFLD cohort, we additionally compared the decision tree model to the widely used NAFLD fibrosis score (NAFLD-FS) <ref type="bibr" target="#b24">[22]</ref> calculated as: -1.675 + 0.037 √ó age (years) + 0.094 √ó BMI + 1.13 √ó hyperglycemia or diabetes (yes = 1, no = 0) + 0.99 √ó AST/ALT ratio ‚àí 0.013 √ó platelet (√ó10 9 /L) ‚àí 0.66 √ó albumin (g/dL) and the Forns' index calculated according to the formula: 7.811-3.131.ln</s><s>(platelet count)+0.781.ln</s><s>(GGT)+3.467.ln</s><s>(age)-0.014.(cholesterol)</s><s><ref type="bibr" target="#b26">[23]</ref>.</s><s>The values for the upper limit of normal for AST were set according to the International Federation of Clinical Chemistry, that is, 35 U/L for men and 30 U/L for women <ref type="bibr" target="#b27">[24]</ref>.</s><s>The values for the upper limit of normal for ALT were 19 U/L in women and 30 U/L in men <ref type="bibr" target="#b27">[24]</ref>.</s><s>The fibrosis risk stratifications for each score were created based on the 2 cutoffs, as described in the original publications.</s><s>They are 0.5 and 1.5 for the APRI <ref type="bibr" target="#b21">[20]</ref>; 1.30 and 2.67 for the FIB-4 score <ref type="bibr" target="#b23">[21]</ref> and -1.455 and 0.676 for the NAFLD-FS <ref type="bibr" target="#b24">[22]</ref> and Forns' index &lt;4.2</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genoytping</head><p><s>Genotyping for IFNL SNPs was undertaken using the TaqMan SNP genotyping allelic discrimination method (Applied Biosystems, Foster City, CA, USA).</s><s>Detailed procedures have been described previously <ref type="bibr" target="#b28">[25]</ref>.</s><s>All genotyping was blinded to clinical variables.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Liver Histopathology</head><p><s>Liver histopathology for patients with CHC and CHB was scored according to METAVIR <ref type="bibr" target="#b16">[17]</ref>.</s><s>Fibrosis was staged from F0 (no fibrosis) to F4 (cirrhosis).</s><s>Necroinflammation (A) was graded as A0 (absent), A1 (mild), A2 (moderate), or A3 (severe).</s><s>For NAFLD, the Kleiner classification was used <ref type="bibr" target="#b30">[26]</ref>.</s><s>Biopsies were interpreted by a single expert liver pathologist in each center who was blinded to patient clinical characteristics, serum measurements and genotyping.</s><s>All biopsies had a minimum of 11 portal tracts, and inadequate biopsies were excluded.</s><s>The inter-observer agreement between pathologists was studied previously and was good (Œ∫ = 77.5)</s><s>for METAVIR staging using Œ∫ statistics <ref type="bibr" target="#b28">[25]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>Statistical analyses were performed using the statistical software package SPSS for Windows, version 21 (SPSS, Chicago, IL), SAS version 9.1 and SAS Enterprise 9.4 (SAS Institute Inc., Cary, NC, USA).</s></p><p><s>Results are expressed as mean ¬± SD (standard deviation) or number (percentage) of patients.</s><s>The Student's t-test or non-parametric, i.e.</s><s>Wilcoxon-Mann-Whitney U-test or Kruskal-Wallis tests were used to compare quantitative data, as appropriate.</s><s>œá 2 and Fisher-exact tests were used for comparison of frequency data and to evaluate the relationships between groups.</s></p><p><s>All tests were two-tailed and p values &lt;0.05 were considered significant.</s><s>Fibrosis progression rate (FPR) was calculated by taking the ratio between the fibrosis stage and the estimated disease duration (in years).</s><s>Patients were stratified into two groups of stage-constant FPR, according to the median rate (0.076 fibrosis units/year) which was used as a cutoff <ref type="bibr" target="#b15">[16]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Development of predictive models using data mining analysis</head><p><s>For the formulation of predictive models, a search for the optimal models was conducted by applying several machine learning techniques, including Multivariate Logistic Regression Analysis (MLRA), Artificial Neural Network (ANN), Decision Tree (DT) and Nearest Neighborhood (KNN) <ref type="bibr" target="#b32">(27)</ref><ref type="bibr" target="#b33">(28)</ref><ref type="bibr" target="#b34">(29)</ref>.</s><s>These statistical methods have been described previously in the field of hepatic diseases <ref type="bibr" target="#b35">[30]</ref><ref type="bibr" target="#b36">[31]</ref><ref type="bibr" target="#b37">[32]</ref>.</s><s>The performance of these techniques was compared.</s></p><p><s>The Dempster-Shafer method <ref type="bibr" target="#b39">[33]</ref> which combines the performance of more than one classifier (MLRA, ANN, DT, KNN) was also investigated for its ability to improve the recognition accuracy of the prediction model.</s><s>To do so, those variables showing a p &lt;0.05 at univariate analysis (Student t test for parametric variables, and œá 2 or Fisher exact test for frequencies) were included in building the model.</s><s>The interaction between these variables was tested.</s><s>Variables explaining a statistically significant proportion of the variance (p &lt;0.05) were maintained in the model using the likelihood ratio (LR) test.</s><s>The model variables were selected using the leave-one-out method to facilitate the calculation of overfit-bias reduced estimates <ref type="bibr" target="#b41">[35]</ref>.</s><s>To avoid overfitting, 10-fold cross validations were used in the tree building process.</s></p><p><s>The discriminative ability of the different classifier techniques for the identification of significant fibrosis (‚â• F2), cirrhosis (F4), and fast FPR (‚â•0.076 fibrosis units/year) was assessed by means of receiver operating characteristic curve analysis and expressed as area under the receiver operating characteristic curve (AUROC).</s><s>Estimates of AUROCs and comparisons between AUROCs used the empirical (nonparametric) method of DeLong et al <ref type="bibr">[34]</ref>.</s><s>In a further analysis, the discriminative ability of the generated DT for the identification of patients classed as slow progressors, intermediate progressors, or rapid progressors according to the tertiles of rate of fibrosis progression was also assessed.</s></p><p><s>External validation was conducted in an independent validation cohort with CHC (n = 1242).</s><s>To ascertain that the validation cohort is well powered to detect a statistically significant difference in model performance considering the number of events (significant fibrosis), sample size estimation was calculated with standard formulas based on the normal distribution <ref type="bibr" target="#b42">[36]</ref>.</s><s>A sample size of n = 1066 was required to achieve 80% power, with 95% CI.</s><s>Some of the characteristics of the validation population were different from those of the derivation population.</s><s>Hence, to ensure robustness of the model, randomly selected sub-cohorts were generated and this process was repeated 10 times; the average of AUROCs in each sub-cohort is reported.</s></p><p><s>Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive and negative likelihood ratio (LHR + , LHR -) and 95% confidence intervals (CIs) were calculated.</s></p><p><s>To overcome both spectrum effect and ordinal scale issues, we undertook two approaches <ref type="bibr" target="#b43">[37,</ref><ref type="bibr" target="#b44">38]</ref>.</s><s>Firstly, we used the Obuchowski measure proposed by Lambert et al. <ref type="bibr" target="#b43">[37]</ref>, which is essentially a multinomial version of the AUROC.</s><s>Each pairwise comparison is weighted to take into account the distance between fibrosis stages (i.e., the number of units on the ordinal scale).</s></p><p><s>A penalty function proportional to the difference in METAVIR units between stages was defined: the penalty function was 0.25 when the difference between stages was 1, 0.50 when the difference was 2 and 1 when the difference was 3. The Obuchowski measure can be interpreted as the probability that the non-invasive index will correctly rank 2 randomly chosen patient samples from different fibrosis stages according to the weighting scheme, with a penalty for misclassifying patients.</s><s>In the second method, we standardized the AUROC for the distribution of fibrosis stages as proposed by Poynard et al. <ref type="bibr" target="#b44">[38]</ref> Briefly, the DANA (Difference between advanced and non-advanced fibrosis = [(prevalence F2 x 2 + prevalence F3 x 3 + prevalence F4</s></p><p><s>x 4)/(prevalence F2 + prevalence F3 + prevalence F4)] -[prevalence F1/(prevalence F0 + prevalence F1)] was calculated <ref type="bibr" target="#b45">[39]</ref> and the adjusted AUROCs determined as follows: AdjAUROC = obAUROC + (0.1056) (2.5-DANA).</s></p><p><s>The prognostic significance of the new model was evaluated by univariate analysis followed by multivariate prognostic analysis using the stepwise Cox proportional hazard regression model in the sub-cohort of patients with an estimated duration of the infection.</s></p><p><s>The missing data on predictive factors were filled in to exclude potential bias derived from missing data by multiple imputation using a stochastic switching regression approach with 5 repeated imputations <ref type="bibr" target="#b46">[40]</ref>.</s><s>Imputation was performed separately on the derivation cohort and the validation cohort, with the predictor variables chosen using the same strategy <ref type="bibr" target="#b46">[40]</ref>.</s><s>Each of the imputed sets was then analyzed as if it were complete, and the results pooled by the method presented by Rubin <ref type="bibr" target="#b47">[41]</ref> to create inferences that validly reflects sampling variability as a result of imputation.</s><s>The imputation method we used is well documented and accepted <ref type="bibr" target="#b46">[40,</ref><ref type="bibr" target="#b47">41]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients' characteristics:</head><p><s>Baseline characteristics of the 1992 CHC patients used to develop the model (derivation cohort) and the 1242 used to test the model (validation cohort) are shown in table 1.</s><s>The derivation and validation cohorts were similar with respect to age at time of biopsy, sex, BMI and HCV-RNA levels, while platelet counts were lower in the validation cohort.</s><s>The distribution of the IFNL rs12979860 responder genotype (CC), daily alcohol consumption over 50g and moderate/severe steatosis were significantly lower in the validation cohort and they had a lower ALT and AST (Table <ref type="table">1</ref>).</s><s>The prevalence of significant fibrosis was similar between the two cohorts (Table <ref type="table">1</ref>).</s><s>The distribution of HCV genotype 1 was the same in the derivation and validation cohorts, while the derivation cohort had more HCV genotype 2 and the validation cohort more HCV genotype 4.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>An IFNL genotype based fibrosis prediction model using data mining analysis</head><p><s>Based on our previous finding that IFNL genotype is associated with fibrosis <ref type="bibr" target="#b15">[16]</ref>, we sought to build a model for the prediction of significant fibrosis based on IFNL genotype, age, gender and routinely assessed clinical and laboratory variables.</s><s>Using data mining analysis, four classifiers MLRA, ANN, DT and KNN, and the combination of more than one classifier were investigated in a systematic unbiased approach.</s><s>The diagnostic accuracy of the four classifiers (MLRA, ANN, KNN and DT) to distinguish between patients in the derivation cohort with and without significant fibrosis (‚â• F2), as indicated by AUROCs, was 0.767, 0.774, 0.768 and 0.804 respectively.</s><s>The sensitivity, specificity, PPV, NPV, LHR+ and LHR-of all models for prediction of significant fibrosis (‚â• F2) are summarized in Table <ref type="table">1</ref> supplementary.</s></p><p><s>In view of the apparent superiority of the decision tree (DT) FibroGENE-DT, compared to other classifiers and its simplicity, this was used in subsequent analysis (Figure <ref type="figure" target="#fig_1">1 A</ref>).</s></p><p><s>Figure <ref type="figure" target="#fig_2">2</ref> depicts the final tree generated by classification and regression tree (CART) analysis along with the significant fibrosis data for each node of this tree.</s><s>These branch points permit patient stratification into 9 risk groups, and in a simple 3-to 4-step process.</s><s>There was high specificity (86%) and PPV (80% certainty of presence of significant fibrosis).</s><s>The AUROC of the model for prediction of severe fibrosis (‚â•F3) was 0.821 (0.95% CI, 0.78-0.86,</s><s>p=0.0001), with 70% sensitivity and 90% NPV and for cirrhosis (F4) was 0.85 (95% CI, 0.79-0.87,</s><s>p = 0.0001), with 86% sensitivity and 98% NPV.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Independent validation of the decision tree</head><p><s>To ascertain the validity of our FibroGENE-DT model generated by CART analysis of the derivation cohort, we tested its ability to predict significant fibrosis in an independent validation cohort (n=1242).</s><s>The baseline characteristics of the validation cohort are shown in table 1.</s></p><p><s>The FibroGENE-DT predicted significant fibrosis with AUROC 0.78 (95% CI: 0.75-0.81)</s><s>(Figure <ref type="figure" target="#fig_1">1</ref> supplementary) with 83% specificity and PPV 79%.</s><s>The AUROCs for the prediction of cirrhosis (F4) was 0.83 (95% CI, 0.78-0.87,</s><s>p = 0.0001), with 82% sensitivity and 96% NPV, reflecting the reliability of the model.</s></p><p><s>In the joint cohort (n=3234), the FibroGENE-DT predicted significant fibrosis with AUROC 0.79 (95% CI, 0.76-82, p = 0.0001) and the AUROC for the prediction of cirrhosis (F4) was 0.838 (95% CI, 0.782-0.86,</s><s>p = 0.0001) with 84% sensitivity and 96% NPV.</s></p><p><s>Adjusted AUROCs <ref type="bibr">(Obuchowski)</ref> showed similar results (Table <ref type="table" target="#tab_1">2</ref> supplementary).</s><s>The sensitivity, specificity, PPV, NPV, LHR+ and LHR-of FibroGENE-DT for prediction of significant fibrosis (‚â• F2), severe fibrosis (‚â• F3) and cirrhosis (F4) in the derivation, validation and joint cohort are summarized in Table <ref type="table" target="#tab_1">2</ref> supplementary.</s><s>Some of the characteristics of the validation population were different from those of the derivation population.</s><s>Hence, to ensure comparability of the two populations, a random distribution was applied.</s><s>The average of the diagnostic accuracy of the FibroGENE-DT in 10 random sub-cohorts had an AUROC 0.792 (95% CI, 0.763-821, p = 0.0001) and the AUROC for the prediction of cirrhosis (F4) was 0.837 (95% CI, 0.788-0.858,</s><s>p = 0.0001).</s><s>These were virtually identical to the full sample estimate (Table <ref type="table" target="#tab_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>An IFNL-based fibrosis prediction model predicts fibrosis progression</head><p><s>We next investigated the validity of the FibroGENE-DT model for the prediction of fast FPR in the sub-cohort of 1242 patients with an estimated date of infection, and hence a known duration of infection.</s><s>Again, the chosen model demonstrated excellent overall performance with AUROC of 0.87 (95% CI: 0.85-0.89,</s><s>p = 0.0001) for the prediction of risk of fast FPR (Figure <ref type="figure" target="#fig_1">1</ref> B).</s><s>The sensitivity, specificity, PPV, NPV, LHR + and LHRwere 81.89%, 91.35%, 92.89%, 78.90%, 9.47 and 0.20, respectively.</s><s>The prognostic value of the model was evaluated in our FPR cohort comparing the cumulative significant fibrosis rates in the high and intermediate/ lowrisk groups over time using a Cox regression model.</s><s>The high risk group compared to the intermediate/low risk group (created by pooling data from the low and intermediate risk groups) had a significantly higher hazard ratio (HR) for significant fibrosis (HR: 3.2, 95% CI: 2.79-4.54,</s><s>p=0.0001) (Figure <ref type="figure" target="#fig_3">3</ref>).</s><s>Finally, the FibroGENE-DT model shows an AUROC of 0.847 (95% CI: 0.817-0.875,</s><s>p=0.0001) for the identification of patients classed as slow progressors, intermediate progressors, or rapid progressors.</s></p><p><s>Subdividing the overall cohort according to HCV genotype (genotype 3 vs.</s><s>non-3) based on the reported association of genotype 3 with fibrosis ( <ref type="formula">16</ref>), the FibroGENE-DT model performance was not significantly different according to HCV-genotype (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparison of the performance of the IFNL fibrosis prediction model with other serum biomarker panels</head><p><s>In both the derivation and validation cohorts, the FibroGENE-DT model was superior (p &lt; 0.05, for all comparisons) to two popular scores (FIB-4 and APRI index) for the prediction of significant fibrosis (‚â• F2) and severe severe fibrosis (‚â• F3) (Table <ref type="table" target="#tab_1">2</ref>).</s><s>FibroGENE-DT was superior to APRI for the prediction of cirrhosis in the derivation cohort.</s><s>It was also significantly superior to FIB-4 in prediction of FPR.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Performance of the model in other liver diseases</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hepatitis B:</head><p><s>The FibroGENE-DT-model performed reasonably well in the cohort with CHB with AUROCs of 0.726 (95% CI: 0.681-0.767)</s><s>for prediction of severe fibrosis (F3-F4) (Figure <ref type="figure" target="#fig_2">2</ref> supplementary), which was higher than the AUC for FIB-4 and APRI indexes (0.655 and 0.705, P &lt;0.05 with FIB-4).</s><s>The AUROC of 0.819 (95% CI: 0.785-0.851)</s><s>for cirrhosis (F4) was also higher than the AUROC for FIB-4 and APRI indexes (0.724, 0.786, p&lt; 0.01, respectively).</s></p><p><s>Adjusted AUROCs <ref type="bibr">(Obuchowski)</ref> showed similar results (Table <ref type="table">3</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>supplementary).</head><p><s>The FibroGENE-DT model had 79% and 92% sensitivity and 86% and 99% NPV for severe fibrosis and cirrhosis, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NAFLD:</head><p><s>We used the same approach for the development of a predictive score in NAFLD as described above for viral hepatitis.</s><s>The FibroGENE-DT -metabolic model incorporated HOMA-IR and thus included IFNL genotype, HOMA-IR, GGT, AST, ALT and platelets (Figure <ref type="figure" target="#fig_3">3</ref> A supplementary).</s><s>The AUROCs of the FibroGENE-DT-metabolic model for prediction of significant fibrosis (F2-4) was (0.791, 95% CI: 0.749-0.828,</s><s>p=0.0001) (Figure <ref type="figure" target="#fig_3">3</ref> B supplementary) which was higher than that of FIB-4, APRI, NAFLD-FS and the Forns' index (0.733, 0.696, 0.743 and 0.721), respectively p&lt;0.05 for all four) (Table <ref type="table">4</ref> supplementary).</s><s>For prediction of severe fibrosis (‚â•F3), AUROCs of the FibroGENE-DT-metabolic model, FIB-4, APRI, NAFLD-FS and Forns' index were 0.807, 0.783, 0.727, 0.79 and 0.786, respectively (p &lt; 0.05 with APRI).</s><s>For the prediction of cirrhosis (F4), AUROCs of the FibroGENE-DTmetabolic model, FIB-4, APRI, NAFLD-FS and Forns' index were 0.839, 0.832, 0.819, 0.821 and 0.816, respectively (p=ns).</s><s>Adjusted AUROCs <ref type="bibr">(Obuchowski)</ref> showed similar results (Table <ref type="table">4</ref> supplementary).</s><s>The IFNL metabolic model had 80% and 98% NPV for significant fibrosis and cirrhosis, respectively.</s><s>In all cohorts (HCV, HBV and NAFLD), the overall measure using the standardization of the AUROC for the distribution of fibrosis stages as described in the methods, of FibroGENE-DT, FIB-4, APRI, NAFLD-FS and Forns' index was similar to observed AUROC curve (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This is the first study to incorporate host genetic polymorphisms into an easy-to-use data mining based index for the prediction of fibrosis stage in liver disease.</s><s>Our analysis of 4277 patients with disease of different etiologies demonstrates that the risk of fast fibrosis progression, significant fibrosis and cirrhosis can be reliably estimated using IFNL genotype, together with routinely available clinical and laboratory data.</s><s>Overall, the algorithm showed good performance, and although the study was not aimed at comparing the accuracy of this model with other models, it showed higher AUROCs than APRI, FIB-4, NFS and the Forns' index in all comparisons and in all cohorts, being applicable not only to CHC, but also to CHB and NAFLD.</s></p><p><s>The extent of liver fibrosis is the most important predictor of long term outcomes in chronic liver diseases, and hence the critical variable for rational decision making <ref type="bibr" target="#b49">[42,</ref><ref type="bibr" target="#b50">43]</ref>, including for variceal and hepatocellular carcinoma screening.</s><s>However, the diagnosis of cirrhosis is frequently missed <ref type="bibr" target="#b51">[44]</ref>, with autopsy studies revealing that up to one third of patients are not identified during their lifetime <ref type="bibr" target="#b52">[45]</ref>.</s><s>Thus, segregating patients with mild or no fibrosis, and hence little chance of liver-related adverse outcomes, from those with more advanced disease or in fact cirrhosis, is crucial.</s><s>When using non-invasive algorithms, models that have the highest negative predictive value (NPV) for cirrhosis are likely to have the most clinical utility <ref type="bibr" target="#b53">[46]</ref>.</s><s>Furthermore, in hepatitis C, accurate fibrosis staging <ref type="bibr" target="#b54">[47,</ref><ref type="bibr" target="#b56">48]</ref> will become even more important in the era of direct acting antiviral treatments, not for assessing eligibility for therapy but for prioritization, particularly in government payer scenarios and in resource poor economies.</s></p><p><s>The high cost of these regimens has already resulted in restrictions to their use in many countries, where only those with advanced disease are eligible for subsidized treatment.</s></p><p><s>We contend that the FibroGENE-DT has immediate clinical utility for the exclusion of subjects with cirrhosis, and in identifying those with a high likelihood of advanced fibrosis in CHC, CHB and NAFLD, and for patient counseling on the risk of rapid fibrosis progression in CHC.</s><s>The FLiP-DT as a first point-of care test excludes the presence of cirrhosis with a negative predictive value &gt;0.96 in CHC, CHB and NAFLD.</s><s>In other scenarios, it could be used in combination with alternative diagnostic modalities such as transient elastography (TE), however this requires further investigation.</s><s>Notably, the FibroGENE-DT could predict fibrosis progression with high accuracy (AUROC = 0.87), a character unique from most of the current available non-invasive modalities of liver fibrosis.</s></p><p><s>The current study has several strengths.</s><s>Firstly, we used a data mining approach, a group of non-parametric regression methods specifically designed for predictive modeling, unlike conventional statistical analysis.</s><s>Second, we utilized a systematic unbiased strategy and compared the performance of four different data mining techniques (MLRA, ANN, DT and KNN).</s><s>We then focused on and validated DT analysis owing to its better performance and simplicity of use, lending the model to bedside clinical practice (Figure <ref type="figure" target="#fig_2">2</ref>).</s><s>This is in contrast to other commonly used multivariable-generated risk models, which are complex due to the mathematical functions involved to interrelate a number of variables.</s><s>Usually, such an approach requires generation of a score to determine risk, making them relatively impractical.</s><s>Even when converted to point scores, the results generated from a multivariate model still needs a nomogram reference to interpret a point score to risk.</s><s>Of relevance, clinical data are not normally distributed, so an advantage of DT analysis is that it does not require parametric assumptions, and therefore it is well suited to handling numerical data that are highly skewed, or alternatively, categorical and multimodal predictors with either an ordinal or non-ordinal structure.</s><s>Finally, the present model was externally validated for hepatitis C, using an independent cohort.</s><s>An earlier study <ref type="bibr" target="#b57">[49]</ref> has defined a genetic signature-based cirrhosis risk score (CRS) consisting of 7 markers.</s><s>This was identified by a genome scan that selected 361 markers in a derivation cohort (N = 420), and then validated a 7 gene signature in a validation cohort of 154 patients.</s><s>The AUROCC of the CRS was 0.75 in the training cohort and 0.73 in the validation cohort.</s><s>Their findings have been shown in other CHC cohorts to be associated with fibrosis progression in patients with mild (METAVIR score of F0-F1) basal fibrosis stage <ref type="bibr" target="#b59">(50,</ref><ref type="bibr" target="#b60">51)</ref>, but not in other chronic liver diseases <ref type="bibr" target="#b61">[52,</ref><ref type="bibr" target="#b62">53]</ref>.</s></p><p><s>Potential limitations of the current analysis must be acknowledged.</s><s>Patients for all cohorts were recruited at tertiary units, which could represent a selection bias.</s><s>However, all cohorts were consecutive and the large number of patients makes this representative of the overall population.</s><s>In addition, each patient's actual risk may be influenced by many factors not measured or considered in the current model.</s><s>We compared Fibrogene-DT to two existing noninvasive indices, FIB-4 and APRI, and in the cohort with NAFLD, also to the NAFLD fibrosis score (NFS) and the Forns' index, that do not require additional laboratory testing.</s><s>However, we were not able to compare it to other existing panels such as Fibrotest, Hepascore, FibroMeter or ELF, which require non-routine laboratory tests and for which additional stored blood was not available.</s><s>Finally, the model had a lower AUROC in CHB compared to CHC.</s><s>However, it is generally accepted that the prediction of fibrosis stage in CHB is more difficult that in CHC, given the fluctuating course of the former <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>.</s></p><p><s>In summary, we have developed a simple clinical tool that allows easy prediction of fibrosis risk in the three most common non-alcoholic causes of chronic liver disease.</s><s>We suggest that the model has immediate applicability where an assessment of liver disease stage is considered important for clinical decision making.</s></p><note type="other">Figure 1A Figure 1B Figure 2 Figure 3</note></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Non-invasive assessment of liver fibrosis stage and prediction of fibrosis progression is an increasing focus of clinical research.</s><s>The most widely utilized approaches are based on serum biomarkers or imaging modalities.</s><s>With advances in our understanding of the genetic contributions to liver fibrosis risk, the incorporation of genetic variants, alone or in combination with or without other clinical variables, seems a logical extension for the development of novel models for fibrosis prediction.</s><s>Further, unlike serum biomarkers or imaging, which might fluctuate based on clinical status and operator factors, genetic markers are robust and invariable between clinical settings.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figures legendsFigure 1 :</head><label>1</label><figDesc><div><p><s>Figures legends</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 :</head><label>2</label><figDesc><div><p><s>Figure 2: FibroGENE-DT for the prediction of significant fibrosis in patients with chronic hepatitis</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: Cumulative probability of progression to moderate/severe (‚â•F2 fibrosis) in 1242 patients</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>1 Table 1 : Demographic and clinical characteristics of the derivation (n =1992) and validation (n = 1242) cohort of patients with chronic hepatitis C</head><label>11</label><figDesc><div><p><s>Data are mean ¬± standard deviation, median and range or as %.</s><s>Liver biopsy data are according to Metavir score.</s></p></div></figDesc><table><row><cell>A3</cell><cell>162 (8.13)</cell><cell>112 (9)</cell><cell>274 (8.47)</cell><cell></cell></row><row><cell>IFNL3 rs12979860 (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CC Variables Age (Years) CT TT Male (%) Alcohol history (%) Caucasian (%) None or less than 50 g/daily (%)</cell><cell>Initial Cohort 807 (40.51) (n=1992) 44.08¬±10.7 44.1 (18-69) 947 (47.54) 238 (11.95) 1251 (62.8) 1827 (91.7) 1471 (73.8)</cell><cell>Replication Cohort 409 (33) (n=1242) 44.7¬±10.9 44 (18-62) 630 (50.7) 203 (16.3) 815 (65.6) 1057 (85.1) 1242 (100)</cell><cell>Overall 1216 (37.6) (n=3234) 44.38¬±10.7 1577 (48.8) 441 (13.6) 44 (18-69) 2066 (63.9) 2884 (89.1) 2713 (83.88)</cell><cell>P-value Initial vs. Replication 0.1 &lt; 0.0001 0.1 &lt; 0.0001 &lt; 0.0001</cell></row><row><cell>‚â• 50 g/daily (%)</cell><cell>521 (26.2)</cell><cell>0 (0)</cell><cell>521 (16.12)</cell><cell></cell></row><row><cell>Steatosis degree</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>None/mild (%)</cell><cell>1756 (88.2)</cell><cell>933 (75.1)</cell><cell>2689 (83.1)</cell><cell></cell></row><row><cell>Moderate severe (%)</cell><cell>236 (11.8)</cell><cell>309 (24.9)</cell><cell>545 (16.9)</cell><cell>&lt; 0.0001</cell></row><row><cell>Liver fibrosis (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>F0</cell><cell>264 (13.3)</cell><cell>152 (12.23)</cell><cell>416 (12.9)</cell><cell></cell></row><row><cell>F1 F2</cell><cell>762 (38.3) 518 (25.9)</cell><cell>531 (42.77) 312 (25.12)</cell><cell>1293 (39.9) 830 (25.7)</cell><cell>0.08</cell></row><row><cell>F3</cell><cell>248 (12.45)</cell><cell>126 (10.14)</cell><cell>374 (11.6)</cell><cell></cell></row><row><cell>F4</cell><cell>200 (10.05)</cell><cell>121 (9.74)</cell><cell>321 (9.9)</cell><cell></cell></row><row><cell>Inflammation score (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>A0</cell><cell>75 (3.77)</cell><cell>49 (3.9)</cell><cell>124 (3.83)</cell><cell></cell></row><row><cell>A1</cell><cell>1048 (52.61)</cell><cell>698 (56.3)</cell><cell>1746 (54)</cell><cell>0.057</cell></row><row><cell>A2</cell><cell>707 (35.49)</cell><cell>383 (30.8)</cell><cell>1090 (33.7)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>2</cell><cell></cell><cell></cell></row></table><note><p><s>*</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 Areas under the Receiver Operating Characteristics curve (AUROCs) for significant fibrosis (‚â•F2), severe fibrosis (‚â•F3), cirrhosis (F4) and fast fibrosis progression rate (FPR) for the AST to platelet ratio index (APRI), FIB-4 and the FibroGENE-DT in patients with chronic viral hepatitis C</head><label>2</label><figDesc></figDesc><table><row><cell></cell><cell>APRI</cell><cell>FIB-4</cell><cell>FibroGENE-DT</cell></row><row><cell></cell><cell></cell><cell>Derivation cohort</cell><cell></cell></row><row><cell>‚â•F2</cell><cell>0.732 (95% CI, 0.692-0.772)</cell><cell>0.747 (95% CI, 0.699-0.790)</cell><cell>0.804 (95% CI, 0.772-0.833)* ‚Ä†</cell></row><row><cell>‚â•F3</cell><cell>0.76 (95% CI,0.741-0.779)</cell><cell>0.778 (95% CI, 0.75-0.796)</cell><cell>0.821 (0.95% CI, 0.781-0.862) * ‚Ä†</cell></row><row><cell>F4</cell><cell>0.79 (95% CI, 0.757-0.820)</cell><cell>0.806 (95% CI, 0.774-0.835)</cell><cell>0.845 (95% CI, 0.794-0.871)*</cell></row><row><cell>Fast FPR</cell><cell>0.805 (95% CI, 0.784-0.827)</cell><cell>0.779 (95% CI, 0.754-0.81)</cell><cell>0.872 (95% CI, 0.851-0.889)  ‚Ä†</cell></row><row><cell></cell><cell></cell><cell>Validation cohort</cell><cell></cell></row><row><cell>‚â•F2</cell><cell>0.75 (95% CI, 0.734-0.805)</cell><cell>0.743 (95% CI, 0.717-0.798)</cell><cell>0.780 (95% CI, 0.754-0.805) * ‚Ä†</cell></row><row><cell>‚â•F3</cell><cell>0.748 (95% CI,0.709)</cell><cell>0.75 (95% CI,0.715-0.783)</cell><cell>0.803 (0.95% CI, 0.774-0.851) * ‚Ä†</cell></row><row><cell>F4</cell><cell>0.812 (95% CI, 0.766-0.860)</cell><cell>0.809 (95% CI, 0.787-0.857)</cell><cell>0.829 (95% CI, 0.784-0.867)</cell></row><row><cell>Fast FPR</cell><cell>0.801 (95% CI, 0.778-0.822)</cell><cell>0.775 (95% CI, 0.751-0.80)</cell><cell>0.866 (95% CI, 0.845-0.886)  ‚Ä†</cell></row><row><cell></cell><cell></cell><cell>Joint cohort</cell><cell></cell></row><row><cell>‚â•F2</cell><cell>0.74 (95% CI, 0.73-0.78)</cell><cell>0.75 (95% CI, 0.69-0.80)</cell><cell>0.79 (95% CI, 0.76-82) * ‚Ä†</cell></row><row><cell>‚â•F3</cell><cell>0.761 (95% CI, 0.75-0.78)</cell><cell>0.775 (95% CI, 0.76-0.789)</cell><cell>0.816 (0.95% CI, 0.793-0.858) * ‚Ä†</cell></row><row><cell>F4</cell><cell>0.80 (95% CI, 0.78-0.85)</cell><cell>0.81 (95% CI, 0.79-0.83)</cell><cell>0.838 (95% CI, 0.782-0.86) *</cell></row></table></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Iredale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="539" to="548" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Viral hepatitis: report by the Secretariat</title>
	</analytic>
	<monogr>
		<title level="j">WHO</title>
		<imprint>
			<date type="published" when="2010-03">March 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Recent advances in NAFLD</title>
		<author>
			<persName><forename type="first">O</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Sanyal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="202" to="208" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Diagnosis and quantitation of fibrosis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Manning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Afdhal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="1670" to="1681" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection</title>
		<author>
			<persName><forename type="first">A</forename><surname>Regev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Berho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Jeffers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Milikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Molina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">T</forename><surname>Pyrsopoulos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="2614" to="2618" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Sampling variability of liver biopsy in nonalcoholic fatty liver disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ratziu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Charlotte</forename><forename type="middle">F</forename><surname>Heurtier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gombert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Giral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bruckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1898" to="1906" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Nonalcoholic steatohepatitis: risk factors and diagnosis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Feldstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="623" to="635" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C</title>
		<author>
			<persName><forename type="first">T</forename><surname>Poynard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Munteanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Imbert-Bismut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Charlotte</forename><forename type="middle">F</forename><surname>Thabut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Calvez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1344" to="1355" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers</title>
		<author>
			<persName><forename type="first">L</forename><surname>Cast√©ra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Bernard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Bail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Foucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Trimoulet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Merrouche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="455" to="465" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases</title>
		<author>
			<persName><forename type="first">B</forename><surname>Coco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Oliveri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Maina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ciccorossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sacco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Colombatto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="360" to="369" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fraquelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rigamonti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Casazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Conte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Donato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ronchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="968" to="973" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Noninvasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B</title>
		<author>
			<persName><forename type="first">P</forename><surname>Marcellin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ziol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bedossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Douvin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Poupon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>De L√©dinghen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Int</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="242" to="247" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases</title>
		<author>
			<persName><forename type="first">F</forename><surname>Oliveri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Coco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ciccorossi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="6154" to="6162" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods</title>
		<author>
			<persName><forename type="first">D</forename><surname>Festi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schiumerini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Marzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Biase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Mandolesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Montrone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="392" to="400" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Yoneda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yoneda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mawatari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fujita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Endo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Iida</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="371" to="378" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">InterferonŒª rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Eslam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Hashem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Romero-Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Dore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">6422</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">An algorithm for the grading of activity in chronic hepatitis C</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bedossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Poynard</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The METAVIR Cooperative Study Group</title>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page">289</biblScope>
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The International Conference on Harmonization Good Clinical Practice guideline</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Dixon</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Qual Assur</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="65" to="74" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">Diagnosis and classification of diabetes mellitus</title>
		<imprint>
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="5" to="10" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Wai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Greenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Fontana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Kalbfleisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Marrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Conjeevaram</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C</title>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="518" to="526" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Sterling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Clumeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Correa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Montaner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1317" to="1325" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<author>
			<persName><forename type="first">P</forename><surname>Angulo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Marchesini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bugianesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Farrell</surname></persName>
		</author>
		<title level="m">The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="846" to="854" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model</title>
		<author>
			<persName><forename type="first">X</forename><surname>Forns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ampurdan√®s</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Llovet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Aponte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Quint√≥</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mart√≠nez-Bauer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="986" to="992" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Updated definitions of healthy ranges for serum alanine aminotransferase levels</title>
		<author>
			<persName><forename type="first">D</forename><surname>Prati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Taioli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zanella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Della</forename><surname>Torre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Butelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Vecchio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Eslam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Romero-Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mangia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Irving</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sheridan</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Hepatol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="235" to="241" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Kleiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Brunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Natta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Behling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Contos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">W</forename><surname>Cummings</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Design and validation of a histological scoring system for nonalcoholic fatty liver disease</title>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1313" to="1321" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Nearest neighbor pattern classification</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Cover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Hart</surname></persName>
		</author>
		<idno>IT-13:21-7</idno>
	</analytic>
	<monogr>
		<title level="j">IEEE Trans Info Theory</title>
		<imprint>
			<date type="published" when="1967">1967</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main">An introduction to classification and regression tree (CART) analysis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Lewis</surname></persName>
		</author>
		<ptr target="http://www.saem.org/download/lewis1.pdf.Accessed" />
		<imprint>
			<date type="published" when="2013-07-08">July 8, 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Application of artificial neural networks to clinical medicine</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Baxt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="issue">8983</biblScope>
			<biblScope unit="page" from="1135" to="1138" />
			<date>1995 8</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Prediction of outcome in acute lower-gastrointestinal haemorrhage based on an artificial neural network: internal and external validation of a predictive model</title>
		<author>
			<persName><forename type="first">A</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ben-Menachem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Sivak</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gonet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="issue">9392</biblScope>
			<biblScope unit="page" from="1261" to="1266" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Pretreatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kurosaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nishida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sakamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Enomoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Honda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="439" to="448" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Hashem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Rasmy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Wahba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">G</forename><surname>Shaker</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Comput Methods Programs Biomed</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="194" to="209" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title level="m" type="main">A Mathematical Theory of Evidence</title>
		<author>
			<persName><forename type="first">G</forename><surname>Shafer</surname></persName>
		</author>
		<imprint>
			<publisher>Princeton University Press</publisher>
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Delong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Delong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Clarke-Pearson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrics</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="837" to="845" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Classifier performance estimation under the constraint of a finite sample size: Resampling schemes applied to neural network classifiers</title>
		<author>
			<persName><forename type="first">B</forename><surname>Sahiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hadjiiski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neural Netw</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="476" to="483" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Substantial effective sample sizes were required for external validation studies of predictive logistic regression models</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Vergouwe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Steyerberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Eijkemans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Habbema</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="475" to="483" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Estimating and comparing diagnostic tests&apos; accuracy when the gold standard is not binary</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Obuchowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acad Radiol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1198" to="1204" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Halfon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Penaranda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1372" to="1378" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages</title>
		<author>
			<persName><forename type="first">T</forename><surname>Poynard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Halfon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Castera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Munteanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Imbert-Bismut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ratziu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1615" to="1622" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Review: a gentle introduction to imputation of missing values</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Donders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Van Der Heijden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Stijnen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Moons</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="1087" to="1091" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<monogr>
		<title level="m" type="main">Multiple imputation: review of theory, implementation and software</title>
		<author>
			<persName><forename type="first">O</forename><surname>Harel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">H</forename><surname>Zhou</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="3057" to="3077" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ekstedt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hagstr√∂m</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nasr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fredrikson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>St√•l</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kechagias</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1547" to="1554" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies</title>
		<author>
			<persName><forename type="first">G</forename><surname>D'amico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Garcia-Tsao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pagliaro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="217" to="231" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies</title>
		<author>
			<persName><forename type="first">N</forename><surname>Graudal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Leth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>M√•rbjerg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Gall√∏e</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Intern Med</title>
		<imprint>
			<biblScope unit="volume">230</biblScope>
			<biblScope unit="page" from="165" to="171" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Undiagnosed cirrhosis occurs frequently in the elderly and requires periodic follow ups and medical treatments</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fujimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sawabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Arai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Geriatr Gerontol Int</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="198" to="203" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Tapper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Castera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Afdhal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="27" to="36" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<monogr>
		<title level="m" type="main">AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations</title>
		<author>
			<persName><forename type="first">C</forename><surname>Koh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Samala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sakiani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Talwalkar</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2142" to="2152" />
			<date>201</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">EASL Clinical Practice Guidelines: management of hepatitis C virus infection</title>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="392" to="420" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<title level="m" type="main">A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C</title>
		<author>
			<persName><forename type="first">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Spann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Venkatesh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bzowej</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">T</forename><surname>Abar</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="297" to="306" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease</title>
		<author>
			<persName><forename type="first">E</forename><surname>Trepo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Potthoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pradat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bakshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lagier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="38" to="44" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">A sevengene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C</title>
		<author>
			<persName><forename type="first">M</forename><surname>Marcolongo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dal</forename><surname>Pero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fattovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Peraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Guido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1038" to="1044" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">The cirrhosis risk score is not associated with liver fibrosis/cirrhosis and fibrosis progression in Chinese nonalcoholic fatty liver disease patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><surname>Wh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">W</forename><surname>Wong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page">S1017</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>5Suppl 1</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Prediction of hepatic fibrosis in patients coinfected with HIV and hepatitis C virus based on genetic markers</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fern√°ndez-Rodr√≠guez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Berenguer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Jim√©nez-Sousa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guzm√°n-Fulgencio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Micheloud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Miralles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Acquir Immune Defic Syndr</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<monogr>
		<title/>
		<author>
			<persName><surname>Hcv-Genotype</surname></persName>
		</author>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page">162</biblScope>
		</imprint>
	</monogr>
	<note>%) 1, 2, 3, 4, 6 1370 (68.8), 210 (10.5). 258 (20.8), 1 (0.1) 2159 (66.8), 242 (7.5), 536 (16.5), 318 (9.8), 6 (0.1</note>
</biblStruct>

<biblStruct xml:id="b64">
	<monogr>
		<title level="m">*p&lt;0.05 compared to APRI; ‚Ä†p&lt;0.05 compared to FIB-4, # p&lt;0.05 compared to NAFLD-FS, ¬∂ p&lt;0.05 compared to Forns&apos; index</title>
				<imprint/>
	</monogr>
	<note>Data are presented as AUROCs (95% confidence interval</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
